ID   PLK1_HUMAN              Reviewed;         603 AA.
AC   P53350; Q15153; Q99746;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   12-OCT-2022, entry version 238.
DE   RecName: Full=Serine/threonine-protein kinase PLK1;
DE            EC=2.7.11.21 {ECO:0000269|PubMed:11202906, ECO:0000269|PubMed:12207013, ECO:0000269|PubMed:21880710};
DE   AltName: Full=Polo-like kinase 1;
DE            Short=PLK-1;
DE   AltName: Full=Serine/threonine-protein kinase 13;
DE            Short=STPK13;
GN   Name=PLK1; Synonyms=PLK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Placenta;
RX   PubMed=8018557;
RA   Hamanaka R., Maloid S., Smith M.R., O'Connell C.D., Longo D.L.,
RA   Ferris D.K.;
RT   "Cloning and characterization of human and murine homologues of the
RT   Drosophila polo serine-threonine kinase.";
RL   Cell Growth Differ. 5:249-257(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=7902533; DOI=10.1128/mcb.13.12.7793-7801.1993;
RA   Lake R.J., Jelinek W.R.;
RT   "Cell cycle- and terminal differentiation-associated regulation of the
RT   mouse mRNA encoding a conserved mitotic protein kinase.";
RL   Mol. Cell. Biol. 13:7793-7801(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=7962193; DOI=10.1242/jcs.107.6.1509;
RA   Golsteyn R.M., Schultz S.J., Bartek J., Ziemiecki A., Ried T., Nigg E.A.;
RT   "Cell cycle analysis and chromosomal localization of human Plk1, a putative
RT   homologue of the mitotic kinases Drosophila polo and Saccharomyces
RT   cerevisiae Cdc5.";
RL   J. Cell Sci. 107:1509-1517(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Lung;
RX   PubMed=8127874; DOI=10.1073/pnas.91.5.1736;
RA   Holtrich U., Wolf G., Braeuninger A., Karn T., Boehme B.,
RA   Ruebsamen-Waigmann H., Strebhardt K.;
RT   "Induction and down-regulation of PLK, a human serine/threonine kinase
RT   expressed in proliferating cells and tumors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:1736-1740(1994).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Colon, and Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-136.
RX   PubMed=7478607;
RA   Brauninger A., Strebhardt K., Rubsamen-Waigmann H.;
RT   "Identification and functional characterization of the human and murine
RT   polo-like kinase (Plk) promoter.";
RL   Oncogene 11:1793-1800(1995).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-136.
RX   PubMed=9083047; DOI=10.1074/jbc.272.14.9166;
RA   Uchiumi T., Longo D.L., Ferris D.K.;
RT   "Cell cycle regulation of the human polo-like kinase (PLK) promoter.";
RL   J. Biol. Chem. 272:9166-9174(1997).
RN   [8]
RP   FUNCTION IN CENTROSOME MATURATION, AND SUBCELLULAR LOCATION.
RX   PubMed=8991084; DOI=10.1083/jcb.135.6.1701;
RA   Lane H.A., Nigg E.A.;
RT   "Antibody microinjection reveals an essential role for human polo-like
RT   kinase 1 (Plk1) in the functional maturation of mitotic centrosomes.";
RL   J. Cell Biol. 135:1701-1713(1996).
RN   [9]
RP   FUNCTION IN PHOSPHORYLATION OF CDC25C.
RX   PubMed=11202906; DOI=10.1016/s0898-6568(00)00080-2;
RA   Roshak A.K., Capper E.A., Imburgia C., Fornwald J., Scott G.,
RA   Marshall L.A.;
RT   "The human polo-like kinase, PLK, regulates cdc2/cyclin B through
RT   phosphorylation and activation of the cdc25C phosphatase.";
RL   Cell. Signal. 12:405-411(2000).
RN   [10]
RP   FUNCTION, PHOSPHORYLATION AT SER-137 AND THR-210, AND MUTAGENESIS OF
RP   LYS-82; SER-137 AND THR-210.
RX   PubMed=12207013; DOI=10.1074/jbc.m202172200;
RA   Jang Y.-J., Ma S., Terada Y., Erikson R.L.;
RT   "Phosphorylation of threonine 210 and the role of serine 137 in the
RT   regulation of mammalian polo-like kinase.";
RL   J. Biol. Chem. 277:44115-44120(2002).
RN   [11]
RP   FUNCTION IN PHOSPHORYLATION OF CCNB1, SUBCELLULAR LOCATION, AND MUTAGENESIS
RP   OF LYS-82 AND THR-210.
RX   PubMed=12447691; DOI=10.1038/sj.onc.1206011;
RA   Yuan J., Eckerdt F., Bereiter-Hahn J., Kurunci-Csacsko E., Kaufmann M.,
RA   Strebhardt K.;
RT   "Cooperative phosphorylation including the activity of polo-like kinase 1
RT   regulates the subcellular localization of cyclin B1.";
RL   Oncogene 21:8282-8292(2002).
RN   [12]
RP   PHOSPHORYLATION AT SER-335.
RX   PubMed=12442251;
RX   DOI=10.1002/1615-9861(200211)2:11<1516::aid-prot1516>3.0.co;2-y;
RA   Wind M., Kelm O., Nigg E.A., Lehmann W.D.;
RT   "Identification of phosphorylation sites in the polo-like kinases Plx1 and
RT   Plk1 by a novel strategy based on element and electrospray high resolution
RT   mass spectrometry.";
RL   Proteomics 2:1516-1523(2002).
RN   [13]
RP   FUNCTION IN PHOSPHORYLATION OF NINL.
RX   PubMed=12852856; DOI=10.1016/s1534-5807(03)00193-x;
RA   Casenghi M., Meraldi P., Weinhart U., Duncan P.I., Korner R., Nigg E.A.;
RT   "Polo-like kinase 1 regulates Nlp, a centrosome protein involved in
RT   microtubule nucleation.";
RL   Dev. Cell 5:113-125(2003).
RN   [14]
RP   PHOSPHORYLATION BY STK10.
RX   PubMed=12639966; DOI=10.1074/jbc.m212556200;
RA   Walter S.A., Cutler R.E. Jr., Martinez R., Gishizky M., Hill R.J.;
RT   "Stk10, a new member of the polo-like kinase kinase family highly expressed
RT   in hematopoietic tissue.";
RL   J. Biol. Chem. 278:18221-18228(2003).
RN   [15]
RP   FUNCTION IN PHOSPHORYLATION OF PKMYT1.
RX   PubMed=12738781; DOI=10.1074/jbc.c300126200;
RA   Nakajima H., Toyoshima-Morimoto F., Taniguchi E., Nishida E.;
RT   "Identification of a consensus motif for Plk (Polo-like kinase)
RT   phosphorylation reveals Myt1 as a Plk1 substrate.";
RL   J. Biol. Chem. 278:25277-25280(2003).
RN   [16]
RP   FUNCTION IN PHOSPHORYLATION OF KIF20A, DOMAIN POLO BOX, SUBCELLULAR
RP   LOCATION, AND INTERACTION WITH KIF20A.
RX   PubMed=12939256; DOI=10.1083/jcb.200306009;
RA   Neef R., Preisinger C., Sutcliffe J., Kopajtich R., Nigg E.A., Mayer T.U.,
RA   Barr F.A.;
RT   "Phosphorylation of mitotic kinesin-like protein 2 by polo-like kinase 1 is
RT   required for cytokinesis.";
RL   J. Cell Biol. 162:863-875(2003).
RN   [17]
RP   FUNCTION IN PHOSPHORYLATION OF CCNB1, AND SUBCELLULAR LOCATION.
RX   PubMed=12524548; DOI=10.1038/ncb918;
RA   Jackman M., Lindon C., Nigg E.A., Pines J.;
RT   "Active cyclin B1-Cdk1 first appears on centrosomes in prophase.";
RL   Nat. Cell Biol. 5:143-148(2003).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND SUBCELLULAR LOCATION [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Lymphoblast;
RX   PubMed=14654843; DOI=10.1038/nature02166;
RA   Andersen J.S., Wilkinson C.J., Mayor T., Mortensen P., Nigg E.A., Mann M.;
RT   "Proteomic characterization of the human centrosome by protein correlation
RT   profiling.";
RL   Nature 426:570-574(2003).
RN   [19]
RP   FUNCTION, PROTEASOMAL DEGRADATION, DOMAIN D-BOX MOTIF, AND MUTAGENESIS OF
RP   ARG-337 AND LEU-340.
RX   PubMed=14734534; DOI=10.1083/jcb.200309035;
RA   Lindon C., Pines J.;
RT   "Ordered proteolysis in anaphase inactivates Plk1 to contribute to proper
RT   mitotic exit in human cells.";
RL   J. Cell Biol. 164:233-241(2004).
RN   [20]
RP   FUNCTION IN PHOSPHORYLATION OF FBXO5.
RX   PubMed=15469984; DOI=10.1091/mbc.e04-07-0598;
RA   Hansen D.V., Loktev A.V., Ban K.H., Jackson P.K.;
RT   "Plk1 regulates activation of the anaphase promoting complex by
RT   phosphorylating and triggering SCFbetaTrCP-dependent destruction of the APC
RT   inhibitor Emi1.";
RL   Mol. Biol. Cell 15:5623-5634(2004).
RN   [21]
RP   FUNCTION IN PHOSPHORYLATION OF WEE1.
RX   PubMed=15070733; DOI=10.1073/pnas.0307700101;
RA   Watanabe N., Arai H., Nishihara Y., Taniguchi M., Watanabe N., Hunter T.,
RA   Osada H.;
RT   "M-phase kinases induce phospho-dependent ubiquitination of somatic Wee1 by
RT   SCFbeta-TrCP.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:4419-4424(2004).
RN   [22]
RP   FUNCTION IN PHOSPHORYLATION OF FBXO5.
RX   PubMed=15148369; DOI=10.1073/pnas.0402442101;
RA   Moshe Y., Boulaire J., Pagano M., Hershko A.;
RT   "Role of Polo-like kinase in the degradation of early mitotic inhibitor 1,
RT   a regulator of the anaphase promoting complex/cyclosome.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:7937-7942(2004).
RN   [23]
RP   FUNCTION IN PHOSPHORYLATION OF CEP55.
RX   PubMed=16198290; DOI=10.1016/j.devcel.2005.09.003;
RA   Fabbro M., Zhou B.-B., Takahashi M., Sarcevic B., Lal P., Graham M.E.,
RA   Gabrielli B.G., Robinson P.J., Nigg E.A., Ono Y., Khanna K.K.;
RT   "Cdk1/Erk2- and Plk1-dependent phosphorylation of a centrosome protein,
RT   Cep55, is required for its recruitment to midbody and cytokinesis.";
RL   Dev. Cell 9:477-488(2005).
RN   [24]
RP   FUNCTION IN PHOSPHORYLATION OF HSF1, AND INTERACTION WITH HSF1.
RX   PubMed=15661742; DOI=10.1074/jbc.m411908200;
RA   Kim S.A., Yoon J.H., Lee S.H., Ahn S.G.;
RT   "Polo-like kinase 1 phosphorylates heat shock transcription factor 1 and
RT   mediates its nuclear translocation during heat stress.";
RL   J. Biol. Chem. 280:12653-12657(2005).
RN   [25]
RP   INTERACTION WITH CEP170.
RX   PubMed=15616186; DOI=10.1091/mbc.e04-10-0939;
RA   Guarguaglini G., Duncan P.I., Stierhof Y.D., Holmstroem T., Duensing S.,
RA   Nigg E.A.;
RT   "The forkhead-associated domain protein Cep170 interacts with Polo-like
RT   kinase 1 and serves as a marker for mature centrioles.";
RL   Mol. Biol. Cell 16:1095-1107(2005).
RN   [26]
RP   INTERACTION WITH EVI5.
RX   PubMed=16439210; DOI=10.1016/j.cell.2005.10.038;
RA   Eldridge A.G., Loktev A.V., Hansen D.V., Verschuren E.W., Reimann J.D.R.,
RA   Jackson P.K.;
RT   "The evi5 oncogene regulates cyclin accumulation by stabilizing the
RT   anaphase-promoting complex inhibitor emi1.";
RL   Cell 124:367-380(2006).
RN   [27]
RP   SUBCELLULAR LOCATION, INTERACTION WITH BUB1 AND BUB1B, AND MUTAGENESIS OF
RP   HIS-538 AND LYS-540.
RX   PubMed=16760428; DOI=10.1091/mbc.e06-03-0240;
RA   Qi W., Tang Z., Yu H.;
RT   "Phosphorylation- and polo-box-dependent binding of Plk1 to Bub1 is
RT   required for the kinetochore localization of Plk1.";
RL   Mol. Biol. Cell 17:3705-3716(2006).
RN   [28]
RP   FUNCTION IN PHOSPHORYLATION OF KIZ.
RX   PubMed=16980960; DOI=10.1038/ncb1474;
RA   Oshimori N., Ohsugi M., Yamamoto T.;
RT   "The Plk1 target Kizuna stabilizes mitotic centrosomes to ensure spindle
RT   bipolarity.";
RL   Nat. Cell Biol. 8:1095-1101(2006).
RN   [29]
RP   FUNCTION IN PHOSPHORYLATION OF ECT2, AND INTERACTION WITH ECT2.
RX   PubMed=16247472; DOI=10.1038/sj.onc.1209124;
RA   Niiya F., Tatsumoto T., Lee K.S., Miki T.;
RT   "Phosphorylation of the cytokinesis regulator ECT2 at G2/M phase stimulates
RT   association of the mitotic kinase Plk1 and accumulation of GTP-bound
RT   RhoA.";
RL   Oncogene 25:827-837(2006).
RN   [30]
RP   FUNCTION IN PHOSPHORYLATION OF CENPU.
RX   PubMed=17081991; DOI=10.1016/j.molcel.2006.10.016;
RA   Kang Y.H., Park J.-E., Yu L.-R., Soung N.-K., Yun S.-M., Bang J.K.,
RA   Seong Y.-S., Yu H., Garfield S., Veenstra T.D., Lee K.S.;
RT   "Self-regulated Plk1 recruitment to kinetochores by the Plk1-PBIP1
RT   interaction is critical for proper chromosome segregation.";
RL   Mol. Cell 24:409-422(2006).
RN   [31]
RP   INVOLVEMENT IN CANCER.
RX   PubMed=16645325; DOI=10.1159/000093003;
RA   Kanaji S., Saito H., Tsujitani S., Matsumoto S., Tatebe S., Kondo A.,
RA   Ozaki M., Ito H., Ikeguchi M.;
RT   "Expression of polo-like kinase 1 (PLK1) protein predicts the survival of
RT   patients with gastric carcinoma.";
RL   Oncology 70:126-133(2006).
RN   [32]
RP   INVOLVEMENT IN CANCER.
RX   PubMed=17981789; DOI=10.1158/0008-5472.can-07-1887;
RA   Salvatore G., Nappi T.C., Salerno P., Jiang Y., Garbi C., Ugolini C.,
RA   Miccoli P., Basolo F., Castellone M.D., Cirafici A.M., Melillo R.M.,
RA   Fusco A., Bittner M.L., Santoro M.;
RT   "A cell proliferation and chromosomal instability signature in anaplastic
RT   thyroid carcinoma.";
RL   Cancer Res. 67:10148-10158(2007).
RN   [33]
RP   INTERACTION WITH ERCC6L.
RX   PubMed=17218258; DOI=10.1016/j.cell.2006.11.041;
RA   Baumann C., Koerner R., Hofmann K., Nigg E.A.;
RT   "PICH, a centromere-associated SNF2 family ATPase, is regulated by Plk1 and
RT   required for the spindle checkpoint.";
RL   Cell 128:101-114(2007).
RN   [34]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=17617734; DOI=10.4161/cc.6.13.4442;
RA   Pouwels J., Kukkonen A.M., Lan W., Daum J.R., Gorbsky G.J., Stukenberg T.,
RA   Kallio M.J.;
RT   "Shugoshin 1 plays a central role in kinetochore assembly and is required
RT   for kinetochore targeting of Plk1.";
RL   Cell Cycle 6:1579-1585(2007).
RN   [35]
RP   INTERACTION WITH TTDN1.
RX   PubMed=17310276; DOI=10.1007/s00018-007-6501-8;
RA   Zhang Y., Tian Y., Chen Q., Chen D., Zhai Z., Shu H.-B.;
RT   "TTDN1 is a Plk1-interacting protein involved in maintenance of cell cycle
RT   integrity.";
RL   Cell. Mol. Life Sci. 64:632-640(2007).
RN   [36]
RP   FUNCTION IN PHOSPHORYLATION OF BUB1B.
RX   PubMed=17376779; DOI=10.1074/jbc.m611053200;
RA   Matsumura S., Toyoshima F., Nishida E.;
RT   "Polo-like kinase 1 facilitates chromosome alignment during prometaphase
RT   through BubR1.";
RL   J. Biol. Chem. 282:15217-15227(2007).
RN   [37]
RP   INVOLVEMENT IN CANCER.
RX   PubMed=17943598; DOI=10.1080/10428190701615918;
RA   Liu L., Zhang M., Zou P.;
RT   "Expression of PLK1 and survivin in diffuse large B-cell lymphoma.";
RL   Leuk. Lymphoma 48:2179-2183(2007).
RN   [38]
RP   FUNCTION IN PHOSPHORYLATION OF PRC1, AND DOMAIN POLO BOX.
RX   PubMed=17351640; DOI=10.1038/ncb1557;
RA   Neef R., Gruneberg U., Kopajtich R., Li X., Nigg E.A., Sillje H.,
RA   Barr F.A.;
RT   "Choice of Plk1 docking partners during mitosis and cytokinesis is
RT   controlled by the activation state of Cdk1.";
RL   Nat. Cell Biol. 9:436-444(2007).
RN   [39]
RP   INTERACTION WITH CYLD, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=17495026; DOI=10.1073/pnas.0703268104;
RA   Stegmeier F., Sowa M.E., Nalepa G., Gygi S.P., Harper J.W., Elledge S.J.;
RT   "The tumor suppressor CYLD regulates entry into mitosis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:8869-8874(2007).
RN   [40]
RP   FUNCTION IN PHOSPHORYLATION OF HSF1, INTERACTION WITH HSF1, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=18794143; DOI=10.1158/0008-5472.can-08-0129;
RA   Lee Y.J., Kim E.H., Lee J.S., Jeoung D., Bae S., Kwon S.H., Lee Y.S.;
RT   "HSF1 as a mitotic regulator: phosphorylation of HSF1 by Plk1 is essential
RT   for mitotic progression.";
RL   Cancer Res. 68:7550-7560(2008).
RN   [41]
RP   UBIQUITINATION BY THE APC/C COMPLEX, INTERACTION WITH FZR1, AND MUTAGENESIS
RP   OF ARG-337 AND LEU-340.
RX   PubMed=18662541; DOI=10.1016/j.cell.2008.05.043;
RA   Bassermann F., Frescas D., Guardavaccaro D., Busino L., Peschiaroli A.,
RA   Pagano M.;
RT   "The Cdc14B-Cdh1-Plk1 axis controls the G2 DNA-damage-response
RT   checkpoint.";
RL   Cell 134:256-267(2008).
RN   [42]
RP   INTERACTION WITH BIRC6/BRUCE.
RX   PubMed=18329369; DOI=10.1016/j.cell.2008.01.012;
RA   Pohl C., Jentsch S.;
RT   "Final stages of cytokinesis and midbody ring formation are controlled by
RT   BRUCE.";
RL   Cell 132:832-845(2008).
RN   [43]
RP   FUNCTION IN PHOSPHORYLATION OF TP73.
RX   PubMed=18418051; DOI=10.4161/cc.7.9.5777;
RA   Soond S.M., Barry S.P., Melino G., Knight R.A., Latchman D.S.,
RA   Stephanou A.;
RT   "p73-mediated transcriptional activity is negatively regulated by polo-like
RT   kinase 1.";
RL   Cell Cycle 7:1214-1223(2008).
RN   [44]
RP   FUNCTION, AND INTERACTION WITH PHOSPHORYLATED BORA.
RX   PubMed=18521620; DOI=10.1007/s00412-008-0165-5;
RA   Chan E.H., Santamaria A., Sillje H.H., Nigg E.A.;
RT   "Plk1 regulates mitotic Aurora A function through betaTrCP-dependent
RT   degradation of hBora.";
RL   Chromosoma 117:457-469(2008).
RN   [45]
RP   FUNCTION IN PHOSPHORYLATION OF SGO1, AND INTERACTION WITH SGO1.
RX   PubMed=18331714; DOI=10.1016/j.devcel.2007.12.007;
RA   Wang X., Yang Y., Duan Q., Jiang N., Huang Y., Darzynkiewicz Z., Dai W.;
RT   "sSgo1, a major splice variant of Sgo1, functions in centriole cohesion
RT   where it is regulated by Plk1.";
RL   Dev. Cell 14:331-341(2008).
RN   [46]
RP   FUNCTION IN PHOSPHORYLATION OF PPP1R12A, PHOSPHORYLATION AT THR-210,
RP   DEPHOSPHORYLATION BY PPP1C, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   HIS-538 AND LYS-540.
RX   PubMed=18477460; DOI=10.1016/j.devcel.2008.02.013;
RA   Yamashiro S., Yamakita Y., Totsukawa G., Goto H., Kaibuchi K., Ito M.,
RA   Hartshorne D.J., Matsumura F.;
RT   "Myosin phosphatase-targeting subunit 1 regulates mitosis by antagonizing
RT   polo-like kinase 1.";
RL   Dev. Cell 14:787-797(2008).
RN   [47]
RP   FUNCTION IN PHOSPHORYLATION OF TP73, AND MUTAGENESIS OF LYS-82.
RX   PubMed=18174154; DOI=10.1074/jbc.m710608200;
RA   Koida N., Ozaki T., Yamamoto H., Ono S., Koda T., Ando K., Okoshi R.,
RA   Kamijo T., Omura K., Nakagawara A.;
RT   "Inhibitory role of Plk1 in the regulation of p73-dependent apoptosis
RT   through physical interaction and phosphorylation.";
RL   J. Biol. Chem. 283:8555-8563(2008).
RN   [48]
RP   INTERACTION WITH FAM29A.
RX   PubMed=19029337; DOI=10.1083/jcb.200807046;
RA   Zhu H., Coppinger J.A., Jang C.-Y., Yates J.R. III, Fang G.;
RT   "FAM29A promotes microtubule amplification via recruitment of the NEDD1-
RT   gamma-tubulin complex to the mitotic spindle.";
RL   J. Cell Biol. 183:835-848(2008).
RN   [49]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-6; SER-103; THR-210; THR-214;
RP   SER-375; SER-450 AND THR-498, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [50]
RP   FUNCTION IN PHOSPHORYLATION OF FOXM1, AND MUTAGENESIS OF LYS-82 AND
RP   THR-210.
RX   PubMed=19160488; DOI=10.1038/ncb1767;
RA   Fu Z., Malureanu L., Huang J., Wang W., Li H., van Deursen J.M.,
RA   Tindall D.J., Chen J.;
RT   "Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional
RT   programme required for mitotic progression.";
RL   Nat. Cell Biol. 10:1076-1082(2008).
RN   [51]
RP   FUNCTION, ACTIVITY REGULATION, PHOSPHORYLATION AT THR-210 BY AURKA,
RP   SUBCELLULAR LOCATION, MUTAGENESIS OF LYS-82; SER-137; ASP-176 AND THR-210,
RP   AND ACTIVE SITE.
RX   PubMed=18615013; DOI=10.1038/nature07185;
RA   Macurek L., Lindqvist A., Lim D., Lampson M.A., Klompmaker R., Freire R.,
RA   Clouin C., Taylor S.S., Yaffe M.B., Medema R.H.;
RT   "Polo-like kinase-1 is activated by aurora A to promote checkpoint
RT   recovery.";
RL   Nature 455:119-123(2008).
RN   [52]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-210 AND THR-214, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [53]
RP   INTERACTION WITH SLX4.
RX   PubMed=19596235; DOI=10.1016/j.cell.2009.06.030;
RA   Svendsen J.M., Smogorzewska A., Sowa M.E., O'Connell B.C., Gygi S.P.,
RA   Elledge S.J., Harper J.W.;
RT   "Mammalian BTBD12/SLX4 assembles a Holliday junction resolvase and is
RT   required for DNA repair.";
RL   Cell 138:63-77(2009).
RN   [54]
RP   FUNCTION IN PHOSPHORYLATION OF TOPORS, AND INTERACTION WITH TOPORS.
RX   PubMed=19473992; DOI=10.1074/jbc.c109.001560;
RA   Yang X., Li H., Zhou Z., Wang W.H., Deng A., Andrisani O., Liu X.;
RT   "Plk1-mediated phosphorylation of Topors regulates p53 stability.";
RL   J. Biol. Chem. 284:18588-18592(2009).
RN   [55]
RP   FUNCTION AS NEDD1 KINASE.
RX   PubMed=19509060; DOI=10.1242/jcs.042747;
RA   Zhang X., Chen Q., Feng J., Hou J., Yang F., Liu J., Jiang Q., Zhang C.;
RT   "Sequential phosphorylation of Nedd1 by Cdk1 and Plk1 is required for
RT   targeting of the gammaTuRC to the centrosome.";
RL   J. Cell Sci. 122:2240-2251(2009).
RN   [56]
RP   FUNCTION, INTERACTION WITH KIF2A, AND SUBCELLULAR LOCATION.
RX   PubMed=19351716; DOI=10.1242/jcs.044321;
RA   Jang C.Y., Coppinger J.A., Seki A., Yates J.R. III, Fang G.;
RT   "Plk1 and Aurora A regulate the depolymerase activity and the cellular
RT   localization of Kif2a.";
RL   J. Cell Sci. 122:1334-1341(2009).
RN   [57]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-210 AND THR-214, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [58]
RP   FUNCTION IN PHOSPHORYLATION OF RACGAP1, INTERACTION WITH PRC1, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=19468300; DOI=10.1371/journal.pbio.1000110;
RA   Wolfe B.A., Takaki T., Petronczki M., Glotzer M.;
RT   "Polo-like kinase 1 directs assembly of the HsCyk-4 RhoGAP/Ect2 RhoGEF
RT   complex to initiate cleavage furrow formation.";
RL   PLoS Biol. 7:E1000110-E1000110(2009).
RN   [59]
RP   FUNCTION IN PHOSPHORYLATION OF RACGAP1, SUBCELLULAR LOCATION, AND
RP   MUTAGENESIS OF CYS-67; LEU-130; HIS-538 AND LYS-540.
RX   PubMed=19468302; DOI=10.1371/journal.pbio.1000111;
RA   Burkard M.E., Maciejowski J., Rodriguez-Bravo V., Repka M., Lowery D.M.,
RA   Clauser K.R., Zhang C., Shokat K.M., Carr S.A., Yaffe M.B.,
RA   Jallepalli P.V.;
RT   "Plk1 self-organization and priming phosphorylation of HsCYK-4 at the
RT   spindle midzone regulate the onset of division in human cells.";
RL   PLoS Biol. 7:E1000111-E1000111(2009).
RN   [60]
RP   REVIEW ON FUNCTION, AND REVIEW ON ACTIVITY REGULATION.
RX   PubMed=20671765; DOI=10.1038/nrd3184;
RA   Strebhardt K.;
RT   "Multifaceted polo-like kinases: drug targets and antitargets for cancer
RT   therapy.";
RL   Nat. Rev. Drug Discov. 9:643-660(2010).
RN   [61]
RP   FUNCTION IN PHOSPHORYLATION OF DCTN1, AND INTERACTION WITH DCTN1.
RX   PubMed=20679239; DOI=10.1073/pnas.1006615107;
RA   Li H., Liu X.S., Yang X., Song B., Wang Y., Liu X.;
RT   "Polo-like kinase 1 phosphorylation of p150Glued facilitates nuclear
RT   envelope breakdown during prophase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:14633-14638(2010).
RN   [62]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-210, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [63]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [64]
RP   FUNCTION IN PHOSPHORYLATION OF RIOK2, AND MUTAGENESIS OF LYS-82.
RX   PubMed=21880710; DOI=10.1074/jbc.m111.250175;
RA   Liu T., Deng M., Li J., Tong X., Wei Q., Ye X.;
RT   "Phosphorylation of right open reading frame 2 (Rio2) protein kinase by
RT   polo-like kinase 1 regulates mitotic progression.";
RL   J. Biol. Chem. 286:36352-36360(2011).
RN   [65]
RP   IDENTIFICATION IN A COMPLEX WITH KNSTRN; SPAG5; DYNLL1 AND SGO2.
RX   PubMed=21402792; DOI=10.1083/jcb.201008023;
RA   Dunsch A.K., Linnane E., Barr F.A., Gruneberg U.;
RT   "The astrin-kinastrin/SKAP complex localizes to microtubule plus ends and
RT   facilitates chromosome alignment.";
RL   J. Cell Biol. 192:959-968(2011).
RN   [66]
RP   INTERACTION WITH FRY, SUBCELLULAR LOCATION, AND MUTAGENESIS OF ASP-194.
RX   PubMed=22753416; DOI=10.1074/jbc.m112.378968;
RA   Ikeda M., Chiba S., Ohashi K., Mizuno K.;
RT   "Furry protein promotes Aurora A-mediated polo-like kinase 1 activation.";
RL   J. Biol. Chem. 287:27670-27681(2012).
RN   [67]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [68]
RP   INTERACTION WITH KLHL22.
RX   PubMed=24067371; DOI=10.4161/cc.25369;
RA   Metzger T., Kleiss C., Sumara I.;
RT   "CUL3 and protein kinases: insights from PLK1/KLHL22 interaction.";
RL   Cell Cycle 12:2291-2296(2013).
RN   [69]
RP   INTERACTION WITH CEP20, SUBCELLULAR LOCATION, AND MUTAGENESIS OF LYS-82;
RP   TRP-414; VAL-415 AND LEU-427.
RX   PubMed=24018379; DOI=10.1038/cr.2013.127;
RA   Shen M., Cai Y., Yang Y., Yan X., Liu X., Zhou T.;
RT   "Centrosomal protein FOR20 is essential for S-phase progression by
RT   recruiting Plk1 to centrosomes.";
RL   Cell Res. 23:1284-1295(2013).
RN   [70]
RP   INTERACTION WITH DCTN6, AND SUBCELLULAR LOCATION.
RX   PubMed=23455152; DOI=10.1038/emboj.2013.30;
RA   Yeh T.Y., Kowalska A.K., Scipioni B.R., Cheong F.K., Zheng M.,
RA   Derewenda U., Derewenda Z.S., Schroer T.A.;
RT   "Dynactin helps target Polo-like kinase 1 to kinetochores via its left-
RT   handed beta-helical p27 subunit.";
RL   EMBO J. 32:1023-1035(2013).
RN   [71]
RP   FUNCTION IN PHOSPHORYLATION OF MISP.
RX   PubMed=23509069; DOI=10.1083/jcb.201207050;
RA   Zhu M., Settele F., Kotak S., Sanchez-Pulido L., Ehret L., Ponting C.P.,
RA   Goenczy P., Hoffmann I.;
RT   "MISP is a novel Plk1 substrate required for proper spindle orientation and
RT   mitotic progression.";
RL   J. Cell Biol. 200:773-787(2013).
RN   [72]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-210, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [73]
RP   FUNCTION, INTERACTION WITH KLHL22, SUBCELLULAR LOCATION, UBIQUITINATION AT
RP   LYS-9 AND LYS-492, AND MUTAGENESIS OF LYS-492.
RX   PubMed=23455478; DOI=10.1038/ncb2695;
RA   Beck J., Maerki S., Posch M., Metzger T., Persaud A., Scheel H.,
RA   Hofmann K., Rotin D., Pedrioli P., Swedlow J.R., Peter M., Sumara I.;
RT   "Ubiquitylation-dependent localization of PLK1 in mitosis.";
RL   Nat. Cell Biol. 15:430-439(2013).
RN   [74]
RP   INTERACTION WITH HNRNPU, AND FUNCTION IN PHOSPHORYLATION OF HNRNPU.
RX   PubMed=25986610; DOI=10.1128/mcb.01312-14;
RA   Douglas P., Ye R., Morrice N., Britton S., Trinkle-Mulcahy L.,
RA   Lees-Miller S.P.;
RT   "Phosphorylation of SAF-A/hnRNP-U serine 59 by polo-like kinase 1 is
RT   required for mitosis.";
RL   Mol. Cell. Biol. 35:2699-2713(2015).
RN   [75]
RP   FUNCTION, AND INTERACTION WITH CEP68.
RX   PubMed=25503564; DOI=10.1038/ncb3076;
RA   Pagan J.K., Marzio A., Jones M.J., Saraf A., Jallepalli P.V., Florens L.,
RA   Washburn M.P., Pagano M.;
RT   "Degradation of Cep68 and PCNT cleavage mediate Cep215 removal from the PCM
RT   to allow centriole separation, disengagement and licensing.";
RL   Nat. Cell Biol. 17:31-43(2015).
RN   [76]
RP   FUNCTION.
RX   PubMed=27979967; DOI=10.1074/jbc.m116.765438;
RA   Zhang B., Wang G., Xu X., Yang S., Zhuang T., Wang G., Ren H., Cheng S.Y.,
RA   Jiang Q., Zhang C.;
RT   "DAZ-interacting Protein 1 (Dzip1) Phosphorylation by Polo-like Kinase 1
RT   (Plk1) Regulates the Centriolar Satellite Localization of the BBSome
RT   Protein during the Cell Cycle.";
RL   J. Biol. Chem. 292:1351-1360(2017).
RN   [77]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-338, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [78]
RP   INTERACTION WITH NEDD9.
RX   PubMed=29191835; DOI=10.1074/jbc.m117.802587;
RA   Lee K.H., Hwang J.A., Kim S.O., Kim J.H., Shin S.C., Kim E.E., Lee K.S.,
RA   Rhee K., Jeon B.H., Bang J.K., Cha-Molstad H., Soung N.K., Jang J.H.,
RA   Ko S.K., Lee H.G., Ahn J.S., Kwon Y.T., Kim B.Y.;
RT   "Phosphorylation of human enhancer filamentation 1 (HEF1) stimulates
RT   interaction with Polo-like kinase 1 leading to HEF1 localization to focal
RT   adhesions.";
RL   J. Biol. Chem. 293:847-862(2018).
RN   [79]
RP   SUBCELLULAR LOCATION.
RX   PubMed=30715179; DOI=10.1093/brain/awz004;
RA   Perez Y., Bar-Yaacov R., Kadir R., Wormser O., Shelef I., Birk O.S.,
RA   Flusser H., Birnbaum R.Y.;
RT   "Mutations in the microtubule-associated protein MAP11 (C7orf43) cause
RT   microcephaly in humans and zebrafish.";
RL   Brain 142:574-585(2019).
RN   [80]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 367-603 IN COMPLEX WITH
RP   PHOSPHORYLATED PEPTIDE, FUNCTION, SUBCELLULAR LOCATION, DOMAIN POLO BOX,
RP   INTERACTION WITH CDC25C, AND MUTAGENESIS OF HIS-538 AND LYS-540.
RX   PubMed=14532005; DOI=10.1016/s0092-8674(03)00725-6;
RA   Elia A.E., Rellos P., Haire L.F., Chao J.W., Ivins F.J., Hoepker K.,
RA   Mohammad D., Cantley L.C., Smerdon S.J., Yaffe M.B.;
RT   "The molecular basis for phosphodependent substrate targeting and
RT   regulation of Plks by the Polo-box domain.";
RL   Cell 115:83-95(2003).
RN   [81]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 367-603 IN COMPLEX WITH
RP   PHOSPHORYLATED PEPTIDE.
RX   PubMed=14592974; DOI=10.1093/emboj/cdg558;
RA   Cheng K.Y., Lowe E.D., Sinclair J., Nigg E.A., Johnson L.N.;
RT   "The crystal structure of the human polo-like kinase-1 polo box domain and
RT   its phospho-peptide complex.";
RL   EMBO J. 22:5757-5768(2003).
RN   [82]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 13-345 OF MUTANT VAL-210 IN
RP   COMPLEXES WITH ATP ANALOGS, AND MUTAGENESIS OF THR-210.
RX   PubMed=17461553; DOI=10.1021/bi602474j;
RA   Kothe M., Kohls D., Low S., Coli R., Cheng A.C., Jacques S.L.,
RA   Johnson T.L., Lewis C., Loh C., Nonomiya J., Sheils A.L., Verdries K.A.,
RA   Wynn T.A., Kuhn C., Ding Y.H.;
RT   "Structure of the catalytic domain of human polo-like kinase 1.";
RL   Biochemistry 46:5960-5971(2007).
RN   [83]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 37-330 IN COMPLEX WITH SYNTHETIC
RP   INHIBITOR BI 2536.
RX   PubMed=18005335; DOI=10.1111/j.1747-0285.2007.00594.x;
RA   Kothe M., Kohls D., Low S., Coli R., Rennie G.R., Feru F., Kuhn C.,
RA   Ding Y.H.;
RT   "Selectivity-determining residues in Plk1.";
RL   Chem. Biol. Drug Des. 70:540-546(2007).
RN   [84]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 365-603 IN COMPLEX WITH CDC25C,
RP   SUBCELLULAR LOCATION, INTERACTION WITH CDC25C, ACTIVITY REGULATION, AND
RP   MUTAGENESIS OF TRP-414.
RX   PubMed=17307877; DOI=10.1073/pnas.0609131104;
RA   Garcia-Alvarez B., de Carcer G., Ibanez S., Bragado-Nilsson E., Montoya G.;
RT   "Molecular and structural basis of polo-like kinase 1 substrate
RT   recognition: Implications in centrosomal localization.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:3107-3112(2007).
RN   [85]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 33-345 IN COMPLEX WITH A DARPIN.
RX   PubMed=18391401; DOI=10.1107/s0907444907068217;
RA   Bandeiras T.M., Hillig R.C., Matias P.M., Eberspaecher U., Fanghanel J.,
RA   Thomaz M., Miranda S., Crusius K., Putter V., Amstutz P.,
RA   Gulotti-Georgieva M., Binz H.K., Holz C., Schmitz A.A., Lang C., Donner P.,
RA   Egner U., Carrondo M.A., Muller-Tiemann B.;
RT   "Structure of wild-type Plk-1 kinase domain in complex with a selective
RT   DARPin.";
RL   Acta Crystallogr. D 64:339-353(2008).
RN   [86]
RP   X-RAY CRYSTALLOGRAPHY (1.58 ANGSTROMS) OF 371-603 IN COMPLEX WITH
RP   PHOSPHOPEPTIDE, FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH
RP   PHOSPHORYLATED CENPU.
RX   PubMed=19597481; DOI=10.1038/nsmb.1628;
RA   Yun S.M., Moulaei T., Lim D., Bang J.K., Park J.E., Shenoy S.R., Liu F.,
RA   Kang Y.H., Liao C., Soung N.K., Lee S., Yoon D.Y., Lim Y., Lee D.H.,
RA   Otaka A., Appella E., McMahon J.B., Nicklaus M.C., Burke T.R. Jr.,
RA   Yaffe M.B., Wlodawer A., Lee K.S.;
RT   "Structural and functional analyses of minimal phosphopeptides targeting
RT   the polo-box domain of polo-like kinase 1.";
RL   Nat. Struct. Mol. Biol. 16:876-882(2009).
RN   [87]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-12; PHE-261; VAL-332; HIS-463 AND
RP   HIS-518.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine-protein kinase that performs several
CC       important functions throughout M phase of the cell cycle, including the
CC       regulation of centrosome maturation and spindle assembly, the removal
CC       of cohesins from chromosome arms, the inactivation of anaphase-
CC       promoting complex/cyclosome (APC/C) inhibitors, and the regulation of
CC       mitotic exit and cytokinesis. Polo-like kinase proteins acts by binding
CC       and phosphorylating proteins are that already phosphorylated on a
CC       specific motif recognized by the POLO box domains. Phosphorylates BORA,
CC       BUB1B/BUBR1, CCNB1, CDC25C, CEP55, ECT2, ERCC6L, FBXO5/EMI1, FOXM1,
CC       KIF20A/MKLP2, CENPU, NEDD1, NINL, NPM1, NUDC, PKMYT1/MYT1, KIZ,
CC       PPP1R12A/MYPT1, PRC1, RACGAP1/CYK4, SGO1, STAG2/SA2, TEX14, TOPORS,
CC       p73/TP73, TPT1, WEE1 and HNRNPU. Plays a key role in centrosome
CC       functions and the assembly of bipolar spindles by phosphorylating KIZ,
CC       NEDD1 and NINL. NEDD1 phosphorylation promotes subsequent targeting of
CC       the gamma-tubulin ring complex (gTuRC) to the centrosome, an important
CC       step for spindle formation. Phosphorylation of NINL component of the
CC       centrosome leads to NINL dissociation from other centrosomal proteins.
CC       Involved in mitosis exit and cytokinesis by phosphorylating CEP55,
CC       ECT2, KIF20A/MKLP2, CENPU, PRC1 and RACGAP1. Recruited at the central
CC       spindle by phosphorylating and docking PRC1 and KIF20A/MKLP2; creates
CC       its own docking sites on PRC1 and KIF20A/MKLP2 by mediating
CC       phosphorylation of sites subsequently recognized by the POLO box
CC       domains. Phosphorylates RACGAP1, thereby creating a docking site for
CC       the Rho GTP exchange factor ECT2 that is essential for the cleavage
CC       furrow formation. Promotes the central spindle recruitment of ECT2.
CC       Plays a central role in G2/M transition of mitotic cell cycle by
CC       phosphorylating CCNB1, CDC25C, FOXM1, CENPU, PKMYT1/MYT1,
CC       PPP1R12A/MYPT1 and WEE1. Part of a regulatory circuit that promotes the
CC       activation of CDK1 by phosphorylating the positive regulator CDC25C and
CC       inhibiting the negative regulators WEE1 and PKMYT1/MYT1. Also acts by
CC       mediating phosphorylation of cyclin-B1 (CCNB1) on centrosomes in
CC       prophase. Phosphorylates FOXM1, a key mitotic transcription regulator,
CC       leading to enhance FOXM1 transcriptional activity. Involved in
CC       kinetochore functions and sister chromatid cohesion by phosphorylating
CC       BUB1B/BUBR1, FBXO5/EMI1 and STAG2/SA2. PLK1 is high on non-attached
CC       kinetochores suggesting a role of PLK1 in kinetochore attachment or in
CC       spindle assembly checkpoint (SAC) regulation. Required for kinetochore
CC       localization of BUB1B. Regulates the dissociation of cohesin from
CC       chromosomes by phosphorylating cohesin subunits such as STAG2/SA2.
CC       Phosphorylates SGO1: required for spindle pole localization of isoform
CC       3 of SGO1 and plays a role in regulating its centriole cohesion
CC       function. Mediates phosphorylation of FBXO5/EMI1, a negative regulator
CC       of the APC/C complex during prophase, leading to FBXO5/EMI1
CC       ubiquitination and degradation by the proteasome. Acts as a negative
CC       regulator of p53 family members: phosphorylates TOPORS, leading to
CC       inhibit the sumoylation of p53/TP53 and simultaneously enhance the
CC       ubiquitination and subsequent degradation of p53/TP53. Phosphorylates
CC       the transactivation domain of the transcription factor p73/TP73,
CC       leading to inhibit p73/TP73-mediated transcriptional activation and
CC       pro-apoptotic functions. Phosphorylates BORA, and thereby promotes the
CC       degradation of BORA. Contributes to the regulation of AURKA function.
CC       Also required for recovery after DNA damage checkpoint and entry into
CC       mitosis. Phosphorylates MISP, leading to stabilization of cortical and
CC       astral microtubule attachments required for proper spindle positioning
CC       (PubMed:8991084, PubMed:11202906, PubMed:12207013, PubMed:12447691,
CC       PubMed:12524548, PubMed:12738781, PubMed:12852856, PubMed:12939256,
CC       PubMed:14532005, PubMed:14734534, PubMed:15070733, PubMed:15148369,
CC       PubMed:15469984, PubMed:16198290, PubMed:16247472, PubMed:16980960,
CC       PubMed:17081991, PubMed:17351640, PubMed:17376779, PubMed:17617734,
CC       PubMed:18174154, PubMed:18331714, PubMed:18418051, PubMed:18477460,
CC       PubMed:18521620, PubMed:18615013, PubMed:19160488, PubMed:19351716,
CC       PubMed:19468300, PubMed:19468302, PubMed:19473992, PubMed:19509060,
CC       PubMed:19597481, PubMed:23455478, PubMed:23509069). Together with
CC       MEIKIN, acts as a regulator of kinetochore function during meiosis I:
CC       required both for mono-orientation of kinetochores on sister
CC       chromosomes and protection of centromeric cohesin from separase-
CC       mediated cleavage (By similarity). Phosphorylates CEP68 and is required
CC       for its degradation (PubMed:25503564). Regulates nuclear envelope
CC       breakdown during prophase by phosphorylating DCTN1 resulting in its
CC       localization in the nuclear envelope (PubMed:20679239). Phosphorylates
CC       the heat shock transcription factor HSF1, promoting HSF1 nuclear
CC       translocation upon heat shock (PubMed:15661742). Phosphorylates HSF1
CC       also in the early mitotic period; this phosphorylation regulates HSF1
CC       localization to the spindle pole, the recruitment of the SCF(BTRC)
CC       ubiquitin ligase complex induicing HSF1 degradation, and hence mitotic
CC       progression (PubMed:18794143). Regulates mitotic progression by
CC       phosphorylating RIOK2 (PubMed:21880710). Through the phosphorylation of
CC       DZIP1 regulates the localization during mitosis of the BBSome, a
CC       ciliary protein complex involved in cilium biogenesis
CC       (PubMed:27979967). {ECO:0000250|UniProtKB:Q5F2C3,
CC       ECO:0000269|PubMed:11202906, ECO:0000269|PubMed:12207013,
CC       ECO:0000269|PubMed:12447691, ECO:0000269|PubMed:12524548,
CC       ECO:0000269|PubMed:12738781, ECO:0000269|PubMed:12852856,
CC       ECO:0000269|PubMed:12939256, ECO:0000269|PubMed:14532005,
CC       ECO:0000269|PubMed:14734534, ECO:0000269|PubMed:15070733,
CC       ECO:0000269|PubMed:15148369, ECO:0000269|PubMed:15469984,
CC       ECO:0000269|PubMed:15661742, ECO:0000269|PubMed:16198290,
CC       ECO:0000269|PubMed:16247472, ECO:0000269|PubMed:16980960,
CC       ECO:0000269|PubMed:17081991, ECO:0000269|PubMed:17351640,
CC       ECO:0000269|PubMed:17376779, ECO:0000269|PubMed:17617734,
CC       ECO:0000269|PubMed:18174154, ECO:0000269|PubMed:18331714,
CC       ECO:0000269|PubMed:18418051, ECO:0000269|PubMed:18477460,
CC       ECO:0000269|PubMed:18521620, ECO:0000269|PubMed:18615013,
CC       ECO:0000269|PubMed:18794143, ECO:0000269|PubMed:19160488,
CC       ECO:0000269|PubMed:19351716, ECO:0000269|PubMed:19468300,
CC       ECO:0000269|PubMed:19468302, ECO:0000269|PubMed:19473992,
CC       ECO:0000269|PubMed:19509060, ECO:0000269|PubMed:19597481,
CC       ECO:0000269|PubMed:20679239, ECO:0000269|PubMed:21880710,
CC       ECO:0000269|PubMed:23455478, ECO:0000269|PubMed:23509069,
CC       ECO:0000269|PubMed:25503564, ECO:0000269|PubMed:25986610,
CC       ECO:0000269|PubMed:27979967, ECO:0000269|PubMed:8991084}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.21;
CC         Evidence={ECO:0000269|PubMed:11202906, ECO:0000269|PubMed:12207013,
CC         ECO:0000269|PubMed:21880710};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.21; Evidence={ECO:0000269|PubMed:11202906,
CC         ECO:0000269|PubMed:12207013, ECO:0000269|PubMed:21880710};
CC   -!- ACTIVITY REGULATION: Activated by phosphorylation of Thr-210 by AURKA;
CC       phosphorylation by AURKA is enhanced by BORA. Once activated, activity
CC       is stimulated by binding target proteins. Binding of target proteins
CC       has no effect on the non-activated kinase. Several inhibitors targeting
CC       PLKs are currently in development and are under investigation in a
CC       growing number of clinical trials, such as BI 2536, an ATP-competitive
CC       PLK1 inhibitor or BI 6727, a dihydropteridinone that specifically
CC       inhibits the catalytic activity of PLK1. {ECO:0000269|PubMed:17307877,
CC       ECO:0000269|PubMed:18615013}.
CC   -!- SUBUNIT: Interacts with CEP170 and EVI5. Interacts and phosphorylates
CC       ERCC6L. Interacts with FAM29A. Interacts with SLX4/BTBD12 and TTDN1.
CC       Interacts with BUB1B. Interacts (via POLO-box domain) with the
CC       phosphorylated form of BUB1, CENPU and CDC25C. Interacts with isoform 3
CC       of SGO1. Interacts with BORA, KIF2A and AURKA. Interacts with TOPORS
CC       and CYLD. Interacts with ECT2; the interaction is stimulated upon
CC       phosphorylation of ECT2 on 'Thr-444'. Interacts with PRC1. Interacts
CC       with KIF20A/MKLP2 (when phosphorylated), leading to the recruitment at
CC       the central spindle. Interacts (via POLO box domains) with
CC       PPP1R12A/MYPT1 (when previously phosphorylated by CDK1). Part of an
CC       astrin (SPAG5)-kinastrin (SKAP) complex containing KNSTRN, SPAG5, PLK1,
CC       DYNLL1 and SGO2. Interacts with BIRC6/bruce. Interacts with CDK1-
CC       phosphorylated FRY; this interaction occurs in mitotic cells, but not
CC       in interphase cells. FRY interaction facilitates AURKA-mediated PLK1
CC       phosphorylation. Interacts with CDK1-phosphorylated DCTN6 during
CC       mitotic prometaphase; the interaction facilitates recruitment to
CC       kinetochores. Interacts with CEP68; the interaction phosphorylates
CC       CEP68 (PubMed:25503564). Interacts (via POLO-box domain) with DCTN1
CC       (PubMed:20679239). Interacts with CEP20 in later G1, S, G2 and M phases
CC       of the cell cycle; this interaction recruits PLK1 to centrosomes, a
CC       step required for S phase progression (PubMed:24018379). Interacts with
CC       HSF1; this interaction increases upon heat shock but does not modulate
CC       neither HSF1 homotrimerization nor DNA-binding activities
CC       (PubMed:15661742, PubMed:18794143). Interacts with HNRNPU; this
CC       interaction induces phosphorylation of HNRNPU in mitosis
CC       (PubMed:25986610). Interacts (via its N-terminus) to RIOK2
CC       (PubMed:21880710). Interacts with KLHL22 (PubMed:24067371,
CC       PubMed:23455478). Interacts (via POLO box domains) with NEDD9/HEF1 (via
CC       C-terminus) (PubMed:29191835). {ECO:0000269|PubMed:12939256,
CC       ECO:0000269|PubMed:14532005, ECO:0000269|PubMed:14592974,
CC       ECO:0000269|PubMed:15616186, ECO:0000269|PubMed:15661742,
CC       ECO:0000269|PubMed:16247472, ECO:0000269|PubMed:16439210,
CC       ECO:0000269|PubMed:16760428, ECO:0000269|PubMed:17218258,
CC       ECO:0000269|PubMed:17307877, ECO:0000269|PubMed:17310276,
CC       ECO:0000269|PubMed:17495026, ECO:0000269|PubMed:18005335,
CC       ECO:0000269|PubMed:18329369, ECO:0000269|PubMed:18331714,
CC       ECO:0000269|PubMed:18391401, ECO:0000269|PubMed:18521620,
CC       ECO:0000269|PubMed:18662541, ECO:0000269|PubMed:18794143,
CC       ECO:0000269|PubMed:19029337, ECO:0000269|PubMed:19351716,
CC       ECO:0000269|PubMed:19468300, ECO:0000269|PubMed:19473992,
CC       ECO:0000269|PubMed:19596235, ECO:0000269|PubMed:19597481,
CC       ECO:0000269|PubMed:20679239, ECO:0000269|PubMed:21402792,
CC       ECO:0000269|PubMed:21880710, ECO:0000269|PubMed:22753416,
CC       ECO:0000269|PubMed:23455152, ECO:0000269|PubMed:23455478,
CC       ECO:0000269|PubMed:24018379, ECO:0000269|PubMed:24067371,
CC       ECO:0000269|PubMed:25503564, ECO:0000269|PubMed:25986610,
CC       ECO:0000269|PubMed:29191835}.
CC   -!- INTERACTION:
CC       P53350; P05067: APP; NbExp=3; IntAct=EBI-476768, EBI-77613;
CC       P53350; O14965: AURKA; NbExp=4; IntAct=EBI-476768, EBI-448680;
CC       P53350; Q9Y2T1: AXIN2; NbExp=2; IntAct=EBI-476768, EBI-4400025;
CC       P53350; Q9NR09: BIRC6; NbExp=4; IntAct=EBI-476768, EBI-1765160;
CC       P53350; P54132: BLM; NbExp=4; IntAct=EBI-476768, EBI-621372;
CC       P53350; Q6PGQ7: BORA; NbExp=5; IntAct=EBI-476768, EBI-719836;
CC       P53350; Q14790: CASP8; NbExp=3; IntAct=EBI-476768, EBI-78060;
CC       P53350; P30307: CDC25C; NbExp=5; IntAct=EBI-476768, EBI-974439;
CC       P53350; Q99741: CDC6; NbExp=6; IntAct=EBI-476768, EBI-374862;
CC       P53350; Q71F23-1: CENPU; NbExp=5; IntAct=EBI-476768, EBI-15793375;
CC       P53350; Q76N32: CEP68; NbExp=2; IntAct=EBI-476768, EBI-9051024;
CC       P53350; O96017: CHEK2; NbExp=7; IntAct=EBI-476768, EBI-1180783;
CC       P53350; O14641: DVL2; NbExp=2; IntAct=EBI-476768, EBI-740850;
CC       P53350; P23588: EIF4B; NbExp=3; IntAct=EBI-476768, EBI-970310;
CC       P53350; Q2NKX8: ERCC6L; NbExp=4; IntAct=EBI-476768, EBI-1042535;
CC       P53350; O60447: EVI5; NbExp=3; IntAct=EBI-476768, EBI-852291;
CC       P53350; Q13158: FADD; NbExp=9; IntAct=EBI-476768, EBI-494804;
CC       P53350; Q9NYZ3: GTSE1; NbExp=6; IntAct=EBI-476768, EBI-2511327;
CC       P53350; P08107: HSPA1B; NbExp=5; IntAct=EBI-476768, EBI-629985;
CC       P53350; O95251: KAT7; NbExp=6; IntAct=EBI-476768, EBI-473199;
CC       P53350; P49736: MCM2; NbExp=2; IntAct=EBI-476768, EBI-374819;
CC       P53350; P33993: MCM7; NbExp=4; IntAct=EBI-476768, EBI-355924;
CC       P53350; Q00987: MDM2; NbExp=7; IntAct=EBI-476768, EBI-389668;
CC       P53350; Q8TD19: NEK9; NbExp=5; IntAct=EBI-476768, EBI-1044009;
CC       P53350; Q5HYW2: NHSL2; NbExp=3; IntAct=EBI-476768, EBI-2859639;
CC       P53350; O75665: OFD1; NbExp=4; IntAct=EBI-476768, EBI-716327;
CC       P53350; Q8IXK0: PHC2; NbExp=2; IntAct=EBI-476768, EBI-713786;
CC       P53350; P53350: PLK1; NbExp=3; IntAct=EBI-476768, EBI-476768;
CC       P53350; P49768-2: PSEN1; NbExp=3; IntAct=EBI-476768, EBI-11047108;
CC       P53350; Q9H0H5: RACGAP1; NbExp=4; IntAct=EBI-476768, EBI-717233;
CC       P53350; Q8IY92: SLX4; NbExp=8; IntAct=EBI-476768, EBI-2370740;
CC       P53350; Q92844: TANK; NbExp=3; IntAct=EBI-476768, EBI-356349;
CC       P53350; Q15583: TGIF1; NbExp=3; IntAct=EBI-476768, EBI-714215;
CC       P53350; P04637: TP53; NbExp=6; IntAct=EBI-476768, EBI-366083;
CC       P53350; Q12888: TP53BP1; NbExp=6; IntAct=EBI-476768, EBI-396540;
CC       P53350; P30291: WEE1; NbExp=2; IntAct=EBI-476768, EBI-914695;
CC       P53350; Q60838: Dvl2; Xeno; NbExp=12; IntAct=EBI-476768, EBI-641940;
CC       P53350; P23804: Mdm2; Xeno; NbExp=2; IntAct=EBI-476768, EBI-641788;
CC       P53350; P70399-1: Tp53bp1; Xeno; NbExp=2; IntAct=EBI-476768, EBI-15790796;
CC       P53350; PRO_0000045602 [Q99IB8]; Xeno; NbExp=4; IntAct=EBI-476768, EBI-6927873;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Chromosome, centromere, kinetochore.
CC       Cytoplasm, cytoskeleton, microtubule organizing center, centrosome
CC       {ECO:0000269|PubMed:14654843, ECO:0000269|PubMed:24018379}. Cytoplasm,
CC       cytoskeleton, spindle {ECO:0000269|PubMed:18794143,
CC       ECO:0000269|PubMed:30715179}. Midbody {ECO:0000269|PubMed:30715179}.
CC       Note=localization at the centrosome starts at the G1/S transition
CC       (PubMed:24018379). During early stages of mitosis, the phosphorylated
CC       form is detected on centrosomes and kinetochores. Localizes to the
CC       outer kinetochore. Presence of SGO1 and interaction with the
CC       phosphorylated form of BUB1 is required for the kinetochore
CC       localization. Localizes onto the central spindle by phosphorylating and
CC       docking at midzone proteins KIF20A/MKLP2 and PRC1. Colocalizes with FRY
CC       to separating centrosomes and spindle poles from prophase to metaphase
CC       in mitosis, but not in other stages of the cell cycle. Localization to
CC       the centrosome is required for S phase progression (PubMed:24018379).
CC       Colocalizes with HSF1 at the spindle poles during prometaphase
CC       (PubMed:18794143). {ECO:0000269|PubMed:18794143,
CC       ECO:0000269|PubMed:24018379}.
CC   -!- TISSUE SPECIFICITY: Placenta and colon.
CC   -!- DEVELOPMENTAL STAGE: Accumulates to a maximum during the G2 and M
CC       phases, declines to a nearly undetectable level following mitosis and
CC       throughout G1 phase, and then begins to accumulate again during S
CC       phase.
CC   -!- INDUCTION: By growth-stimulating agents.
CC   -!- DOMAIN: The POLO box domains act as phosphopeptide-binding module that
CC       recognize and bind serine-[phosphothreonine/phosphoserine]-(proline/X)
CC       motifs. PLK1 recognizes and binds docking proteins that are already
CC       phosphorylated on these motifs, and then phosphorylates them. PLK1 can
CC       also create its own docking sites by mediating phosphorylation of
CC       serine-[phosphothreonine/phosphoserine]-(proline/X) motifs subsequently
CC       recognized by the POLO box domains. {ECO:0000269|PubMed:12939256,
CC       ECO:0000269|PubMed:14532005, ECO:0000269|PubMed:14734534,
CC       ECO:0000269|PubMed:17351640}.
CC   -!- PTM: Catalytic activity is enhanced by phosphorylation of Thr-210.
CC       Phosphorylation at Thr-210 is first detected on centrosomes in the G2
CC       phase of the cell cycle, peaks in prometaphase and gradually disappears
CC       from centrosomes during anaphase. Dephosphorylation at Thr-210 at
CC       centrosomes is probably mediated by protein phosphatase 1C (PP1C), via
CC       interaction with PPP1R12A/MYPT1. Autophosphorylation and
CC       phosphorylation of Ser-137 may not be significant for the activation of
CC       PLK1 during mitosis, but may enhance catalytic activity during recovery
CC       after DNA damage checkpoint. Phosphorylated in vitro by STK10.
CC       {ECO:0000269|PubMed:12207013, ECO:0000269|PubMed:12442251,
CC       ECO:0000269|PubMed:12639966, ECO:0000269|PubMed:18477460,
CC       ECO:0000269|PubMed:18615013}.
CC   -!- PTM: Ubiquitinated by the anaphase promoting complex/cyclosome (APC/C)
CC       in anaphase and following DNA damage, leading to its degradation by the
CC       proteasome. Ubiquitination is mediated via its interaction with
CC       FZR1/CDH1. Ubiquitination and subsequent degradation prevents entry
CC       into mitosis and is essential to maintain an efficient G2 DNA damage
CC       checkpoint. Monoubiquitination at Lys-492 by the BCR(KLHL22) ubiquitin
CC       ligase complex does not lead to degradation: it promotes PLK1
CC       dissociation from phosphoreceptor proteins and subsequent removal from
CC       kinetochores, allowing silencing of the spindle assembly checkpoint
CC       (SAC) and chromosome segregation. {ECO:0000269|PubMed:18662541,
CC       ECO:0000269|PubMed:23455478}.
CC   -!- DISEASE: Note=Defects in PLK1 are associated with some cancers, such as
CC       gastric, thyroid or B-cell lymphomas. Expression is cancer increased in
CC       tumor tissues with a poor prognosis, suggesting a role in malignant
CC       transformations and carcinogenesis.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein
CC       kinase family. CDC5/Polo subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PLK1ID41747ch16p12.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U01038; AAA56634.1; -; mRNA.
DR   EMBL; L19559; AAA36659.1; -; mRNA.
DR   EMBL; X73458; CAA51837.1; -; mRNA.
DR   EMBL; X75932; CAA53536.1; -; mRNA.
DR   EMBL; BC002369; AAH02369.1; -; mRNA.
DR   EMBL; BC003002; AAH03002.1; -; mRNA.
DR   EMBL; BC014846; AAH14846.1; -; mRNA.
DR   EMBL; X90725; CAA62260.1; -; Genomic_DNA.
DR   EMBL; U78073; AAB36946.1; -; Genomic_DNA.
DR   CCDS; CCDS10616.1; -.
DR   PIR; S34130; S34130.
DR   RefSeq; NP_005021.2; NM_005030.5.
DR   PDB; 1Q4K; X-ray; 2.30 A; A/B/C=345-603.
DR   PDB; 1Q4O; X-ray; 2.20 A; A/B=367-603.
DR   PDB; 1UMW; X-ray; 1.90 A; A/B=367-603.
DR   PDB; 2OGQ; X-ray; 1.95 A; A=365-603.
DR   PDB; 2OJX; X-ray; 2.85 A; A=365-603.
DR   PDB; 2OU7; X-ray; 2.40 A; A=13-345.
DR   PDB; 2OWB; X-ray; 2.10 A; A=13-345.
DR   PDB; 2RKU; X-ray; 1.95 A; A=37-330.
DR   PDB; 2V5Q; X-ray; 2.30 A; A/B=33-345.
DR   PDB; 2YAC; X-ray; 2.20 A; A=36-345.
DR   PDB; 3BZI; X-ray; 2.10 A; A=365-603.
DR   PDB; 3C5L; X-ray; 2.33 A; A=373-593.
DR   PDB; 3FC2; X-ray; 2.45 A; A=13-345.
DR   PDB; 3FVH; X-ray; 1.58 A; A=371-603.
DR   PDB; 3HIH; X-ray; 1.70 A; A/B=371-593.
DR   PDB; 3HIK; X-ray; 1.77 A; A=367-603.
DR   PDB; 3KB7; X-ray; 2.50 A; A=36-345.
DR   PDB; 3P2W; X-ray; 1.66 A; A=371-594.
DR   PDB; 3P2Z; X-ray; 1.79 A; A=371-594.
DR   PDB; 3P34; X-ray; 1.40 A; A=371-594.
DR   PDB; 3P35; X-ray; 2.09 A; A/B/C=371-594.
DR   PDB; 3P36; X-ray; 1.59 A; A=371-594.
DR   PDB; 3P37; X-ray; 2.38 A; A/B/C=371-594.
DR   PDB; 3Q1I; X-ray; 1.40 A; A=371-594.
DR   PDB; 3RQ7; X-ray; 1.55 A; A=371-603.
DR   PDB; 3THB; X-ray; 2.50 A; A=13-345.
DR   PDB; 4A4L; X-ray; 2.35 A; A=36-345.
DR   PDB; 4A4O; X-ray; 2.70 A; A=36-345.
DR   PDB; 4DFW; X-ray; 1.55 A; A=367-603.
DR   PDB; 4E67; X-ray; 2.10 A; A=371-594.
DR   PDB; 4E9C; X-ray; 1.70 A; A=371-594.
DR   PDB; 4E9D; X-ray; 2.75 A; A=371-594.
DR   PDB; 4H5X; X-ray; 1.95 A; A/B=367-603.
DR   PDB; 4H71; X-ray; 1.93 A; A/B=367-603.
DR   PDB; 4HAB; X-ray; 2.65 A; A/B/C=371-593.
DR   PDB; 4HCO; X-ray; 2.75 A; A/B=367-603.
DR   PDB; 4HY2; X-ray; 2.00 A; A=371-595.
DR   PDB; 4J52; X-ray; 2.30 A; A=38-330.
DR   PDB; 4J53; X-ray; 2.50 A; A=38-330.
DR   PDB; 4LKL; X-ray; 1.58 A; A=372-593.
DR   PDB; 4LKM; X-ray; 2.00 A; A/C=371-601.
DR   PDB; 4O56; X-ray; 1.80 A; A=367-603.
DR   PDB; 4O6W; X-ray; 1.45 A; A=371-603.
DR   PDB; 4O9W; X-ray; 1.69 A; A=373-594.
DR   PDB; 4RCP; X-ray; 1.60 A; A=372-599.
DR   PDB; 4WHH; X-ray; 1.90 A; A=371-603.
DR   PDB; 4WHK; X-ray; 1.80 A; A=371-603.
DR   PDB; 4WHL; X-ray; 2.71 A; A=371-603.
DR   PDB; 4X9R; X-ray; 1.40 A; A=371-603.
DR   PDB; 4X9V; X-ray; 1.43 A; A=371-603.
DR   PDB; 4X9W; X-ray; 1.80 A; A=371-603.
DR   PDB; 5J19; X-ray; 2.00 A; A/B=367-594.
DR   PDB; 5NEI; X-ray; 2.68 A; A=371-603.
DR   PDB; 5NFU; X-ray; 1.81 A; A=371-602.
DR   PDB; 5NJE; X-ray; 1.98 A; A=371-603.
DR   PDB; 5NMM; X-ray; 2.02 A; A=371-603.
DR   PDB; 5NN1; X-ray; 1.78 A; A=371-603.
DR   PDB; 5NN2; X-ray; 1.81 A; A=371-594.
DR   PDB; 5TA6; X-ray; 2.50 A; A=13-345.
DR   PDB; 5TA8; X-ray; 2.60 A; A=13-345.
DR   PDB; 6AX4; X-ray; 1.45 A; A=371-603.
DR   PDB; 6GY2; X-ray; 3.11 A; A/B=365-603.
DR   PDB; 7MSO; X-ray; 1.85 A; A/B=371-603.
DR   PDB; 7MX1; X-ray; 1.64 A; A/B=371-603.
DR   PDBsum; 1Q4K; -.
DR   PDBsum; 1Q4O; -.
DR   PDBsum; 1UMW; -.
DR   PDBsum; 2OGQ; -.
DR   PDBsum; 2OJX; -.
DR   PDBsum; 2OU7; -.
DR   PDBsum; 2OWB; -.
DR   PDBsum; 2RKU; -.
DR   PDBsum; 2V5Q; -.
DR   PDBsum; 2YAC; -.
DR   PDBsum; 3BZI; -.
DR   PDBsum; 3C5L; -.
DR   PDBsum; 3FC2; -.
DR   PDBsum; 3FVH; -.
DR   PDBsum; 3HIH; -.
DR   PDBsum; 3HIK; -.
DR   PDBsum; 3KB7; -.
DR   PDBsum; 3P2W; -.
DR   PDBsum; 3P2Z; -.
DR   PDBsum; 3P34; -.
DR   PDBsum; 3P35; -.
DR   PDBsum; 3P36; -.
DR   PDBsum; 3P37; -.
DR   PDBsum; 3Q1I; -.
DR   PDBsum; 3RQ7; -.
DR   PDBsum; 3THB; -.
DR   PDBsum; 4A4L; -.
DR   PDBsum; 4A4O; -.
DR   PDBsum; 4DFW; -.
DR   PDBsum; 4E67; -.
DR   PDBsum; 4E9C; -.
DR   PDBsum; 4E9D; -.
DR   PDBsum; 4H5X; -.
DR   PDBsum; 4H71; -.
DR   PDBsum; 4HAB; -.
DR   PDBsum; 4HCO; -.
DR   PDBsum; 4HY2; -.
DR   PDBsum; 4J52; -.
DR   PDBsum; 4J53; -.
DR   PDBsum; 4LKL; -.
DR   PDBsum; 4LKM; -.
DR   PDBsum; 4O56; -.
DR   PDBsum; 4O6W; -.
DR   PDBsum; 4O9W; -.
DR   PDBsum; 4RCP; -.
DR   PDBsum; 4WHH; -.
DR   PDBsum; 4WHK; -.
DR   PDBsum; 4WHL; -.
DR   PDBsum; 4X9R; -.
DR   PDBsum; 4X9V; -.
DR   PDBsum; 4X9W; -.
DR   PDBsum; 5J19; -.
DR   PDBsum; 5NEI; -.
DR   PDBsum; 5NFU; -.
DR   PDBsum; 5NJE; -.
DR   PDBsum; 5NMM; -.
DR   PDBsum; 5NN1; -.
DR   PDBsum; 5NN2; -.
DR   PDBsum; 5TA6; -.
DR   PDBsum; 5TA8; -.
DR   PDBsum; 6AX4; -.
DR   PDBsum; 6GY2; -.
DR   PDBsum; 7MSO; -.
DR   PDBsum; 7MX1; -.
DR   AlphaFoldDB; P53350; -.
DR   SMR; P53350; -.
DR   BioGRID; 111362; 446.
DR   CORUM; P53350; -.
DR   DIP; DIP-29696N; -.
DR   ELM; P53350; -.
DR   IntAct; P53350; 265.
DR   MINT; P53350; -.
DR   STRING; 9606.ENSP00000300093; -.
DR   BindingDB; P53350; -.
DR   ChEMBL; CHEMBL3024; -.
DR   DrugBank; DB07789; 1-[5-Methyl-2-(trifluoromethyl)furan-3-yl]-3-[5-[2-[[6-(1H-1,2,4-triazol-5-ylamino)pyrimidin-4-yl]amino]ethyl]-1,3-thiazol-2-yl]urea.
DR   DrugBank; DB06963; 3-[3-(3-methyl-6-{[(1S)-1-phenylethyl]amino}-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl]propanamide.
DR   DrugBank; DB06897; 3-[3-chloro-5-(5-{[(1S)-1-phenylethyl]amino}isoxazolo[5,4-c]pyridin-3-yl)phenyl]propan-1-ol.
DR   DrugBank; DB07186; 4-(4-METHYLPIPERAZIN-1-YL)-N-[5-(2-THIENYLACETYL)-1,5-DIHYDROPYRROLO[3,4-C]PYRAZOL-3-YL]BENZAMIDE.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB08059; Wortmannin.
DR   DrugCentral; P53350; -.
DR   GuidetoPHARMACOLOGY; 2168; -.
DR   MoonDB; P53350; Curated.
DR   GlyGen; P53350; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; P53350; -.
DR   PhosphoSitePlus; P53350; -.
DR   SwissPalm; P53350; -.
DR   BioMuta; PLK1; -.
DR   DMDM; 1709658; -.
DR   CPTAC; CPTAC-1264; -.
DR   CPTAC; CPTAC-1326; -.
DR   CPTAC; CPTAC-1327; -.
DR   EPD; P53350; -.
DR   jPOST; P53350; -.
DR   MassIVE; P53350; -.
DR   MaxQB; P53350; -.
DR   PaxDb; P53350; -.
DR   PeptideAtlas; P53350; -.
DR   PRIDE; P53350; -.
DR   ProteomicsDB; 56569; -.
DR   Antibodypedia; 12634; 1225 antibodies from 47 providers.
DR   DNASU; 5347; -.
DR   Ensembl; ENST00000300093.9; ENSP00000300093.4; ENSG00000166851.15.
DR   GeneID; 5347; -.
DR   KEGG; hsa:5347; -.
DR   MANE-Select; ENST00000300093.9; ENSP00000300093.4; NM_005030.6; NP_005021.2.
DR   UCSC; uc002dlz.2; human.
DR   CTD; 5347; -.
DR   DisGeNET; 5347; -.
DR   GeneCards; PLK1; -.
DR   HGNC; HGNC:9077; PLK1.
DR   HPA; ENSG00000166851; Tissue enhanced (bone marrow, lymphoid tissue, testis).
DR   MIM; 602098; gene.
DR   neXtProt; NX_P53350; -.
DR   OpenTargets; ENSG00000166851; -.
DR   PharmGKB; PA33410; -.
DR   VEuPathDB; HostDB:ENSG00000166851; -.
DR   eggNOG; KOG0575; Eukaryota.
DR   GeneTree; ENSGT00940000157752; -.
DR   HOGENOM; CLU_000288_46_1_1; -.
DR   InParanoid; P53350; -.
DR   OMA; LKHFERY; -.
DR   OrthoDB; 507604at2759; -.
DR   PhylomeDB; P53350; -.
DR   TreeFam; TF101089; -.
DR   BRENDA; 2.7.11.21; 2681.
DR   PathwayCommons; P53350; -.
DR   Reactome; R-HSA-141444; Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal.
DR   Reactome; R-HSA-156711; Polo-like kinase mediated events.
DR   Reactome; R-HSA-162658; Golgi Cisternae Pericentriolar Stack Reorganization.
DR   Reactome; R-HSA-174178; APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1.
DR   Reactome; R-HSA-176412; Phosphorylation of the APC/C.
DR   Reactome; R-HSA-176417; Phosphorylation of Emi1.
DR   Reactome; R-HSA-2299718; Condensation of Prophase Chromosomes.
DR   Reactome; R-HSA-2467813; Separation of Sister Chromatids.
DR   Reactome; R-HSA-2500257; Resolution of Sister Chromatid Cohesion.
DR   Reactome; R-HSA-2565942; Regulation of PLK1 Activity at G2/M Transition.
DR   Reactome; R-HSA-2980767; Activation of NIMA Kinases NEK9, NEK6, NEK7.
DR   Reactome; R-HSA-380259; Loss of Nlp from mitotic centrosomes.
DR   Reactome; R-HSA-380270; Recruitment of mitotic centrosome proteins and complexes.
DR   Reactome; R-HSA-380284; Loss of proteins required for interphase microtubule organization from the centrosome.
DR   Reactome; R-HSA-380320; Recruitment of NuMA to mitotic centrosomes.
DR   Reactome; R-HSA-5620912; Anchoring of the basal body to the plasma membrane.
DR   Reactome; R-HSA-5663220; RHO GTPases Activate Formins.
DR   Reactome; R-HSA-68877; Mitotic Prometaphase.
DR   Reactome; R-HSA-68881; Mitotic Metaphase/Anaphase Transition.
DR   Reactome; R-HSA-68884; Mitotic Telophase/Cytokinesis.
DR   Reactome; R-HSA-69273; Cyclin A/B1/B2 associated events during G2/M transition.
DR   Reactome; R-HSA-8852276; The role of GTSE1 in G2/M progression after G2 checkpoint.
DR   Reactome; R-HSA-8854518; AURKA Activation by TPX2.
DR   Reactome; R-HSA-9648025; EML4 and NUDC in mitotic spindle formation.
DR   SignaLink; P53350; -.
DR   SIGNOR; P53350; -.
DR   BioGRID-ORCS; 5347; 839 hits in 1107 CRISPR screens.
DR   ChiTaRS; PLK1; human.
DR   EvolutionaryTrace; P53350; -.
DR   GeneWiki; PLK1; -.
DR   GenomeRNAi; 5347; -.
DR   Pharos; P53350; Tchem.
DR   PRO; PR:P53350; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   RNAct; P53350; protein.
DR   Bgee; ENSG00000166851; Expressed in ventricular zone and 101 other tissues.
DR   ExpressionAtlas; P53350; baseline and differential.
DR   Genevisible; P53350; HS.
DR   GO; GO:0034451; C:centriolar satellite; IEA:Ensembl.
DR   GO; GO:0005814; C:centriole; IEA:Ensembl.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0000785; C:chromatin; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0000776; C:kinetochore; IDA:UniProtKB.
DR   GO; GO:0015630; C:microtubule cytoskeleton; IDA:BHF-UCL.
DR   GO; GO:0030496; C:midbody; IDA:UniProtKB.
DR   GO; GO:0097431; C:mitotic spindle pole; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0000940; C:outer kinetochore; IDA:BHF-UCL.
DR   GO; GO:0005819; C:spindle; IDA:UniProtKB.
DR   GO; GO:0051233; C:spindle midzone; IDA:UniProtKB.
DR   GO; GO:0000922; C:spindle pole; IDA:BHF-UCL.
DR   GO; GO:0000795; C:synaptonemal complex; IEA:Ensembl.
DR   GO; GO:0010997; F:anaphase-promoting complex binding; IPI:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IMP:CAFA.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0000287; F:magnesium ion binding; IMP:CAFA.
DR   GO; GO:0008017; F:microtubule binding; IDA:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0007098; P:centrosome cycle; IMP:UniProtKB.
DR   GO; GO:0000132; P:establishment of mitotic spindle orientation; IDA:UniProtKB.
DR   GO; GO:0045184; P:establishment of protein localization; IMP:MGI.
DR   GO; GO:0016321; P:female meiosis chromosome segregation; IEA:Ensembl.
DR   GO; GO:0000086; P:G2/M transition of mitotic cell cycle; IDA:UniProtKB.
DR   GO; GO:0045143; P:homologous chromosome segregation; IEA:Ensembl.
DR   GO; GO:0001578; P:microtubule bundle formation; IDA:UniProtKB.
DR   GO; GO:0000278; P:mitotic cell cycle; IDA:UniProtKB.
DR   GO; GO:0007076; P:mitotic chromosome condensation; TAS:Reactome.
DR   GO; GO:0000281; P:mitotic cytokinesis; IDA:UniProtKB.
DR   GO; GO:0007095; P:mitotic G2 DNA damage checkpoint signaling; IDA:UniProtKB.
DR   GO; GO:0007077; P:mitotic nuclear membrane disassembly; TAS:Reactome.
DR   GO; GO:0000070; P:mitotic sister chromatid segregation; IMP:UniProtKB.
DR   GO; GO:0007094; P:mitotic spindle assembly checkpoint signaling; IMP:UniProtKB.
DR   GO; GO:0007052; P:mitotic spindle organization; TAS:Reactome.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0045736; P:negative regulation of cyclin-dependent protein serine/threonine kinase activity; IMP:BHF-UCL.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IMP:UniProtKB.
DR   GO; GO:0051081; P:nuclear membrane disassembly; IMP:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0010800; P:positive regulation of peptidyl-threonine phosphorylation; IMP:BHF-UCL.
DR   GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IMP:UniProtKB.
DR   GO; GO:1900182; P:positive regulation of protein localization to nucleus; TAS:Reactome.
DR   GO; GO:0045862; P:positive regulation of proteolysis; IDA:UniProtKB.
DR   GO; GO:1904668; P:positive regulation of ubiquitin protein ligase activity; IDA:UniProtKB.
DR   GO; GO:0051443; P:positive regulation of ubiquitin-protein transferase activity; IMP:UniProtKB.
DR   GO; GO:0031648; P:protein destabilization; IDA:UniProtKB.
DR   GO; GO:0071168; P:protein localization to chromatin; IDA:UniProtKB.
DR   GO; GO:0090435; P:protein localization to nuclear envelope; IMP:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0016567; P:protein ubiquitination; IDA:UniProtKB.
DR   GO; GO:1905784; P:regulation of anaphase-promoting complex-dependent catabolic process; TAS:Reactome.
DR   GO; GO:0051726; P:regulation of cell cycle; TAS:Reactome.
DR   GO; GO:0032465; P:regulation of cytokinesis; IDA:UniProtKB.
DR   GO; GO:0007346; P:regulation of mitotic cell cycle; IMP:UniProtKB.
DR   GO; GO:1901990; P:regulation of mitotic cell cycle phase transition; TAS:Reactome.
DR   GO; GO:0030071; P:regulation of mitotic metaphase/anaphase transition; IDA:UniProtKB.
DR   GO; GO:1901673; P:regulation of mitotic spindle assembly; IDA:CACAO.
DR   GO; GO:0043393; P:regulation of protein binding; IMP:BHF-UCL.
DR   GO; GO:1904776; P:regulation of protein localization to cell cortex; IDA:UniProtKB.
DR   GO; GO:0007062; P:sister chromatid cohesion; TAS:Reactome.
DR   GO; GO:0070194; P:synaptonemal complex disassembly; IEA:Ensembl.
DR   CDD; cd13118; POLO_box_1; 1.
DR   CDD; cd13117; POLO_box_2; 1.
DR   CDD; cd14187; STKc_PLK1; 1.
DR   Gene3D; 3.30.1120.30; -; 2.
DR   IDEAL; IID00200; -.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR033702; PLK1_cat.
DR   InterPro; IPR033701; POLO_box_1.
DR   InterPro; IPR033695; POLO_box_2.
DR   InterPro; IPR000959; POLO_box_dom.
DR   InterPro; IPR036947; POLO_box_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00659; POLO_box; 2.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50078; POLO_BOX; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; ATP-binding; Cell cycle; Cell division;
KW   Centromere; Chromosome; Cytoplasm; Cytoskeleton; Isopeptide bond; Kinase;
KW   Kinetochore; Mitosis; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Reference proteome; Repeat; Serine/threonine-protein kinase; Transferase;
KW   Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0007744|PubMed:22814378"
FT   CHAIN           2..603
FT                   /note="Serine/threonine-protein kinase PLK1"
FT                   /id="PRO_0000086556"
FT   DOMAIN          53..305
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          417..480
FT                   /note="POLO box 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00154"
FT   DOMAIN          515..584
FT                   /note="POLO box 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00154"
FT   REGION          1..35
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          194..221
FT                   /note="Activation loop"
FT   REGION          338..364
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          493..507
FT                   /note="Linker"
FT   REGION          538..540
FT                   /note="Important for interaction with phosphorylated
FT                   proteins"
FT                   /evidence="ECO:0000250"
FT   MOTIF           337..340
FT                   /note="D-box that targets the protein for proteasomal
FT                   degradation in anaphase"
FT   COMPBIAS        350..364
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        176
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000269|PubMed:18615013"
FT   BINDING         59..67
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   BINDING         82
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   BINDING         131
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   BINDING         178..181
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   BINDING         194
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   MOD_RES         2
FT                   /note="N-acetylserine"
FT                   /evidence="ECO:0007744|PubMed:22814378"
FT   MOD_RES         6
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         103
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         137
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000305|PubMed:12207013"
FT   MOD_RES         210
FT                   /note="Phosphothreonine; by AURKA"
FT                   /evidence="ECO:0000269|PubMed:12207013,
FT                   ECO:0000269|PubMed:18477460, ECO:0000269|PubMed:18615013,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         214
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195"
FT   MOD_RES         269
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         335
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:12442251"
FT   MOD_RES         375
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         450
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         498
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   CROSSLNK        19
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:18662541"
FT   CROSSLNK        338
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        492
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:23455478"
FT   VARIANT         12
FT                   /note="R -> L (in a lung squamous cell carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041018"
FT   VARIANT         261
FT                   /note="L -> F (in dbSNP:rs35056440)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041019"
FT   VARIANT         297
FT                   /note="N -> D (in dbSNP:rs16972799)"
FT                   /id="VAR_051659"
FT   VARIANT         332
FT                   /note="L -> V (in dbSNP:rs45489499)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041020"
FT   VARIANT         463
FT                   /note="L -> H (in dbSNP:rs45569335)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041021"
FT   VARIANT         518
FT                   /note="R -> H (in dbSNP:rs56027600)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041022"
FT   VARIANT         595
FT                   /note="S -> L (in dbSNP:rs34001032)"
FT                   /id="VAR_051660"
FT   VARIANT         599
FT                   /note="R -> H (in dbSNP:rs34954545)"
FT                   /id="VAR_051661"
FT   MUTAGEN         67
FT                   /note="C->V: In analog-sensitive mutant; enlarged catalytic
FT                   pocket to accommodate purine analogs; when associated with
FT                   G-130."
FT                   /evidence="ECO:0000269|PubMed:19468302"
FT   MUTAGEN         82
FT                   /note="K->M: Loss of kinase activity. No effect on S-phase
FT                   progression."
FT                   /evidence="ECO:0000269|PubMed:12207013,
FT                   ECO:0000269|PubMed:12447691, ECO:0000269|PubMed:18174154,
FT                   ECO:0000269|PubMed:24018379"
FT   MUTAGEN         82
FT                   /note="K->R: Loss of kinase activity. No effect on
FT                   RIOK2-binding."
FT                   /evidence="ECO:0000269|PubMed:18615013,
FT                   ECO:0000269|PubMed:19160488, ECO:0000269|PubMed:21880710"
FT   MUTAGEN         130
FT                   /note="L->G: In analog-sensitive mutant; enlarged catalytic
FT                   pocket to accommodate purine analogs; when associated with
FT                   V-67."
FT                   /evidence="ECO:0000269|PubMed:19468302"
FT   MUTAGEN         137
FT                   /note="S->A: No change in activity. Increases activity and
FT                   restores recovery after DNA damage checkpoint; when
FT                   associated with D-210."
FT                   /evidence="ECO:0000269|PubMed:12207013,
FT                   ECO:0000269|PubMed:18615013"
FT   MUTAGEN         137
FT                   /note="S->D: Increases activity. Results in a block in
FT                   G1/S."
FT                   /evidence="ECO:0000269|PubMed:12207013,
FT                   ECO:0000269|PubMed:18615013"
FT   MUTAGEN         176
FT                   /note="D->N: Abolishes kinase activity."
FT                   /evidence="ECO:0000269|PubMed:18615013"
FT   MUTAGEN         194
FT                   /note="D->A: Does not interfere with FRY-binding."
FT                   /evidence="ECO:0000269|PubMed:22753416"
FT   MUTAGEN         210
FT                   /note="T->A: Abolishes activity. Abolishes checkpoint
FT                   recovery."
FT                   /evidence="ECO:0000269|PubMed:12207013,
FT                   ECO:0000269|PubMed:12447691, ECO:0000269|PubMed:17461553,
FT                   ECO:0000269|PubMed:18615013, ECO:0000269|PubMed:19160488"
FT   MUTAGEN         210
FT                   /note="T->D: Increases activity and restores recovery after
FT                   DNA damage checkpoint."
FT                   /evidence="ECO:0000269|PubMed:12207013,
FT                   ECO:0000269|PubMed:12447691, ECO:0000269|PubMed:17461553,
FT                   ECO:0000269|PubMed:18615013, ECO:0000269|PubMed:19160488"
FT   MUTAGEN         210
FT                   /note="T->V: Reduced catalytic activity, but no effect on
FT                   affinity for ATP."
FT                   /evidence="ECO:0000269|PubMed:12207013,
FT                   ECO:0000269|PubMed:12447691, ECO:0000269|PubMed:17461553,
FT                   ECO:0000269|PubMed:18615013, ECO:0000269|PubMed:19160488"
FT   MUTAGEN         337
FT                   /note="R->A: Interferes with ubiquitination and subsequent
FT                   proteasomal degradation in anaphase; when associated with
FT                   A-340."
FT                   /evidence="ECO:0000269|PubMed:14734534,
FT                   ECO:0000269|PubMed:18662541"
FT   MUTAGEN         340
FT                   /note="L->A: Interferes with ubiquitination and subsequent
FT                   proteasomal degradation in anaphase; when associated with
FT                   A-337."
FT                   /evidence="ECO:0000269|PubMed:14734534,
FT                   ECO:0000269|PubMed:18662541"
FT   MUTAGEN         414
FT                   /note="W->F: Abolishes interaction with CDC25C and reduces
FT                   centrosomal localization."
FT                   /evidence="ECO:0000269|PubMed:17307877"
FT   MUTAGEN         414
FT                   /note="W->F: No effect on centrosomal localization, nor on
FT                   S-phase progression; when asscociated with A-427. Loss of
FT                   centrosomal localization and of S-phase progression; when
FT                   associated with A- 415 and A-427."
FT                   /evidence="ECO:0000269|PubMed:24018379"
FT   MUTAGEN         415
FT                   /note="V->A: Loss of centrosomal localization and of
FT                   S-phase progression; when associated with A- 414 and
FT                   A-427."
FT                   /evidence="ECO:0000269|PubMed:24018379"
FT   MUTAGEN         427
FT                   /note="L->A: No effect on centrosomal localization, nor on
FT                   S-phase progression; when associated with A-414. Loss of
FT                   centrosomal localization and of S-phase progression; when
FT                   associated with A- 414 and A-415."
FT                   /evidence="ECO:0000269|PubMed:24018379"
FT   MUTAGEN         492
FT                   /note="K->R: Severe mitotic defects leading to prometaphase
FT                   delay. Increased localization at kinetochores leading to
FT                   increased levels of phosphorylated BUBR1."
FT                   /evidence="ECO:0000269|PubMed:23455478"
FT   MUTAGEN         538
FT                   /note="H->A: In pincer mutant; loss of centrosomal location
FT                   and decreased interaction with phosphorylated CDC25C and
FT                   BUB1; when associated with M-540."
FT                   /evidence="ECO:0000269|PubMed:14532005,
FT                   ECO:0000269|PubMed:16760428, ECO:0000269|PubMed:18477460,
FT                   ECO:0000269|PubMed:19468302"
FT   MUTAGEN         540
FT                   /note="K->M: In pincer mutant; loss of centrosomal location
FT                   and decreased interaction with phosphorylated CDC25C and
FT                   BUB1; when associated with A-538."
FT                   /evidence="ECO:0000269|PubMed:14532005,
FT                   ECO:0000269|PubMed:16760428, ECO:0000269|PubMed:18477460,
FT                   ECO:0000269|PubMed:19468302"
FT   CONFLICT        2
FT                   /note="S -> T (in Ref. 1; AAA56634)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        11
FT                   /note="A -> P (in Ref. 1; AAA56634)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        58
FT                   /note="F -> L (in Ref. 1; AAA56634)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        60
FT                   /note="G -> S (in Ref. 1; AAA56634)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        73
FT                   /note="A -> V (in Ref. 2; AAA36659 and 7; AAB36946)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        123
FT                   /note="N -> T (in Ref. 6; CAA62260)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        141
FT                   /note="L -> P (in Ref. 4; CAA53536)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        227
FT                   /note="G -> E (in Ref. 4; CAA53536)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        301
FT                   /note="N -> G (in Ref. 2; AAA36659)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        495
FT                   /note="A -> G (in Ref. 2; AAA36659)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        501
FT                   /note="E -> Q (in Ref. 2; AAA36659)"
FT                   /evidence="ECO:0000305"
FT   STRAND          42..46
FT                   /evidence="ECO:0007829|PDB:2RKU"
FT   TURN            47..50
FT                   /evidence="ECO:0007829|PDB:2RKU"
FT   STRAND          51..62
FT                   /evidence="ECO:0007829|PDB:2RKU"
FT   STRAND          65..72
FT                   /evidence="ECO:0007829|PDB:2RKU"
FT   TURN            73..75
FT                   /evidence="ECO:0007829|PDB:2RKU"
FT   STRAND          78..85
FT                   /evidence="ECO:0007829|PDB:2RKU"
FT   HELIX           86..88
FT                   /evidence="ECO:0007829|PDB:2RKU"
FT   HELIX           92..106
FT                   /evidence="ECO:0007829|PDB:2RKU"
FT   STRAND          116..121
FT                   /evidence="ECO:0007829|PDB:2RKU"
FT   STRAND          123..131
FT                   /evidence="ECO:0007829|PDB:2RKU"
FT   HELIX           138..145
FT                   /evidence="ECO:0007829|PDB:2RKU"
FT   HELIX           150..169
FT                   /evidence="ECO:0007829|PDB:2RKU"
FT   HELIX           179..181
FT                   /evidence="ECO:0007829|PDB:2RKU"
FT   STRAND          182..184
FT                   /evidence="ECO:0007829|PDB:2RKU"
FT   STRAND          190..192
FT                   /evidence="ECO:0007829|PDB:2RKU"
FT   HELIX           220..223
FT                   /evidence="ECO:0007829|PDB:2RKU"
FT   STRAND          224..226
FT                   /evidence="ECO:0007829|PDB:2V5Q"
FT   HELIX           231..246
FT                   /evidence="ECO:0007829|PDB:2RKU"
FT   HELIX           256..264
FT                   /evidence="ECO:0007829|PDB:2RKU"
FT   HELIX           276..285
FT                   /evidence="ECO:0007829|PDB:2RKU"
FT   HELIX           290..292
FT                   /evidence="ECO:0007829|PDB:2RKU"
FT   HELIX           296..301
FT                   /evidence="ECO:0007829|PDB:2RKU"
FT   HELIX           303..306
FT                   /evidence="ECO:0007829|PDB:2RKU"
FT   HELIX           316..319
FT                   /evidence="ECO:0007829|PDB:2RKU"
FT   HELIX           367..370
FT                   /evidence="ECO:0007829|PDB:5J19"
FT   HELIX           374..386
FT                   /evidence="ECO:0007829|PDB:4X9R"
FT   HELIX           389..391
FT                   /evidence="ECO:0007829|PDB:4X9R"
FT   STRAND          392..394
FT                   /evidence="ECO:0007829|PDB:3P34"
FT   HELIX           397..400
FT                   /evidence="ECO:0007829|PDB:4X9R"
FT   HELIX           403..405
FT                   /evidence="ECO:0007829|PDB:4X9R"
FT   STRAND          411..417
FT                   /evidence="ECO:0007829|PDB:4X9R"
FT   TURN            418..421
FT                   /evidence="ECO:0007829|PDB:4X9R"
FT   STRAND          422..427
FT                   /evidence="ECO:0007829|PDB:4X9R"
FT   STRAND          432..436
FT                   /evidence="ECO:0007829|PDB:4X9R"
FT   STRAND          441..444
FT                   /evidence="ECO:0007829|PDB:4X9R"
FT   STRAND          448..454
FT                   /evidence="ECO:0007829|PDB:4X9R"
FT   STRAND          460..464
FT                   /evidence="ECO:0007829|PDB:4X9R"
FT   TURN            465..467
FT                   /evidence="ECO:0007829|PDB:3Q1I"
FT   HELIX           470..472
FT                   /evidence="ECO:0007829|PDB:4X9R"
FT   HELIX           473..488
FT                   /evidence="ECO:0007829|PDB:4X9R"
FT   TURN            493..496
FT                   /evidence="ECO:0007829|PDB:4X9R"
FT   TURN            503..505
FT                   /evidence="ECO:0007829|PDB:3P34"
FT   STRAND          511..516
FT                   /evidence="ECO:0007829|PDB:4X9R"
FT   STRAND          518..525
FT                   /evidence="ECO:0007829|PDB:4X9R"
FT   TURN            526..528
FT                   /evidence="ECO:0007829|PDB:4WHL"
FT   STRAND          530..534
FT                   /evidence="ECO:0007829|PDB:4X9R"
FT   TURN            535..537
FT                   /evidence="ECO:0007829|PDB:4X9R"
FT   STRAND          540..544
FT                   /evidence="ECO:0007829|PDB:4X9R"
FT   TURN            545..548
FT                   /evidence="ECO:0007829|PDB:4X9R"
FT   STRAND          549..553
FT                   /evidence="ECO:0007829|PDB:4X9R"
FT   STRAND          559..563
FT                   /evidence="ECO:0007829|PDB:4X9R"
FT   HELIX           564..570
FT                   /evidence="ECO:0007829|PDB:4X9R"
FT   HELIX           574..591
FT                   /evidence="ECO:0007829|PDB:4X9R"
FT   STRAND          593..595
FT                   /evidence="ECO:0007829|PDB:4O56"
FT   STRAND          598..602
FT                   /evidence="ECO:0007829|PDB:4O56"
SQ   SEQUENCE   603 AA;  68255 MW;  178C2F13C10E8206 CRC64;
     MSAAVTAGKL ARAPADPGKA GVPGVAAPGA PAAAPPAKEI PEVLVDPRSR RRYVRGRFLG
     KGGFAKCFEI SDADTKEVFA GKIVPKSLLL KPHQREKMSM EISIHRSLAH QHVVGFHGFF
     EDNDFVFVVL ELCRRRSLLE LHKRRKALTE PEARYYLRQI VLGCQYLHRN RVIHRDLKLG
     NLFLNEDLEV KIGDFGLATK VEYDGERKKT LCGTPNYIAP EVLSKKGHSF EVDVWSIGCI
     MYTLLVGKPP FETSCLKETY LRIKKNEYSI PKHINPVAAS LIQKMLQTDP TARPTINELL
     NDEFFTSGYI PARLPITCLT IPPRFSIAPS SLDPSNRKPL TVLNKGLENP LPERPREKEE
     PVVRETGEVV DCHLSDMLQQ LHSVNASKPS ERGLVRQEEA EDPACIPIFW VSKWVDYSDK
     YGLGYQLCDN SVGVLFNDST RLILYNDGDS LQYIERDGTE SYLTVSSHPN SLMKKITLLK
     YFRNYMSEHL LKAGANITPR EGDELARLPY LRTWFRTRSA IILHLSNGSV QINFFQDHTK
     LILCPLMAAV TYIDEKRDFR TYRLSLLEEY GCCKELASRL RYARTMVDKL LSSRSASNRL
     KAS
//
